Alys Pharmaceuticals launches with $100 Million financing from Medicxi
Share this article
Formed through the aggregation of six-asset centric Medicxi companies, including Aldena Therapeutics, Alys boasts a robust R&D pipeline of cutting-edge programmes and platforms targeting multiple dermatological indications.
Co-founded by Medicxi and several world-leading dermatology and scientific experts, Alys is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company.
It combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. With more than a dozen active programs, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses.
Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies.
Source: press release